Unicentric Castleman disease (UCD) is a rare disorder of the lymphatic system characterized by lymphatic tissue hyperplasia, often localized to a single node. This pathology may be asymptomatic or with clinical manifestations associated with compression of adjacent structures. UCD can have different morphological subtypes, including follicular, giant cell, and vascular. There is a link between UCD and human herpes virus type 8 (HHV-8), but not all cases are associated with the infection. Despite its unclear etiology, this disease requires timely diagnosis and medical intervention to prevent complications.
History of the disease and interesting historical facts
Unicentric Castleman disease was first described in 1956 by Dr. Daniel Castleman, who observed patients with enlarged lymph nodes and characteristic embryonic cells in their tissue. In the early days of the disease, classic cases of UCD were often ignored or misdiagnosed as lymphomas or other lymphatic diseases. Of particular interest is the fact that, despite its rarity, the disease attracted the attention of researchers, which contributed to the understanding of the immunological activity of lymphatic tissue. Various subtypes of the disease were subsequently identified, which expanded the diagnosis and therapeutic approaches to the condition. In recent decades, advances in molecular biology and genetics have greatly advanced the understanding and diagnosis of the disease.
Epidemiology
Unicentric Castleman disease is rare. Some epidemiological studies estimate the incidence to be between 0.5 and 1 case per 100,000 persons per year. The age of onset varies, but UCD is most commonly diagnosed in people aged 30 to 50 years. There is no significant difference in prevalence by sex, but there is a slight predisposition to the disease in men. In some populations, particularly in persons with HIV infection, the incidence of UCD is increasing, highlighting the importance of epidemiological analysis in different populations.
Genetic predisposition to this disease
There are no clear genetic mutations directly associated with unicentric Castleman disease. However, in some cases, studies have shown that changes in proto-oncogenes such as MYC may be associated with the development of lymphatic hyperplasia. There is also information about the influence of human herpes virus type 8 (HHV-8), which has been reported to cause changes in immune function and precede the development of UCD in some patients. However, the question of genetic predisposition requires further study, and potential changes in other genes remain unclear.
Risk factors for the development of this disease
Known risk factors associated with unicentric Castleman disease include:
- Human herpes virus type 8 (HHV-8) infection
- Immunodeficiency states, including HIV infection
- Exposure to certain chemicals, such as hormones and carcinogens
- Age: the main risk group is people aged 30-50 years
- Gender: slight predisposition in males
- Genetic factors, although the exact genes have not yet been identified
Thus, a combination of factors may contribute to the development of UCD, but the clinical mechanism remains unclear and requires further study.
Diagnosis of this disease
Diagnosis of unicentric Castleman disease is based on a combination of clinical and instrumental methods:
- Main symptoms may include swollen lymph nodes, fever, sweating, malaise and weight loss.
- Laboratory tests are aimed at identifying anemia, elevated levels of inflammatory markers (eg, C-reactive protein), and imbalances in the cellular composition of the blood.
- Radiological tests such as computed tomography (CT) scan or magnetic resonance imaging (MRI) can help visualize enlarged lymph nodes and assess their spread.
- Lymph node biopsy plays a key role in confirming the diagnosis, allowing for morphological and immunohistochemical examination.
- Differential diagnosis includes lymphomas, reactive lymphadenopathies and other conditions requiring careful data analysis.
A comprehensive approach to diagnosing UCD is critical for appropriate treatment.
Treatment
Treatment for unicentric Castleman disease may vary depending on the clinical presentation and stage of the disease. The main approaches to therapy include:
- General treatment is aimed at symptomatic improvement: prescribing anti-inflammatory drugs, managing associated symptoms (eg, fever and sweating).
- Pharmacological treatment includes the use of steroids and immunosuppressive drugs such as rituximab, which help control the disease.
- Surgical treatment is the main method, especially when there is a single lymph node with access that allows resection of the node and assessment of its pathology.
- Other treatments may include radiation therapy if indicated, although this is a less common approach.
It is important to take into account that the choice of method depends on the individual characteristics of the patient, including the overall clinical picture and concomitant diseases.
List of medications used to treat this disease
Medications used to treat unicentric Castleman disease may include:
- Glucocorticosteroids (eg, prednisolone)
- Rituximab
- Cyclophosphamide
- Lenalidomide
- Trastuzumab (for HHV-8-associated cancers)
Each of these drugs has its own indications and side effects, and their use should be carried out under the supervision of a specialist.
Disease monitoring
Monitoring of unicentric Castleman disease involves periodic examinations and follow-up observation of the patient's condition, which allows:
- Determine the effectiveness of the treatment and the need for its correction.
- Monitor for possible relapses or complications of the disease.
- Evaluate laboratory data and control parameters of other organ functions.
The prognosis with early diagnosis and adequate treatment is generally favorable, although there is a risk of relapse or development of concomitant diseases.
Age-related features of the disease
Unicentric Castleman disease may present in different age groups, but is most common in adults aged 30 to 50 years. In children and adolescents, UCD cases are mostly anachronistic and may present differently. In older patients, the disease may be more aggressive and require more intensive monitoring and treatment. Differences in clinical presentation and course may be related to the immune response in different age groups.
Questions and Answers
- What is unicentric Castleman disease? This is a rare disease of the lymphatic system, characterized by hyperplasia of lymphatic tissue and localized in one lymph node.
- How is UCD diagnosed? Diagnosis includes analysis of clinical symptoms, laboratory tests, radiological examinations and lymph node biopsy.
- What treatments are used for UCD? Treatment may include surgery, pharmacological treatment using steroids and immunosuppressants.
- What is the prognosis for unicentric Castleman disease? The prognosis is favorable with timely diagnosis and treatment, although relapses are possible.
- Who is at risk for developing UCD? At risk are people aged 30-50 years, as well as patients with HIV and HHV-8 infection.
